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Abstract
Background: A good correlation between HCV core antigen (HCVAg) and different HCV-RNA assays has been
described, but little data are available in HCV/HIV co-infection. We aimed to evaluate HCVAg in comparison with
HCV-RNA and to determine their kinetics during antiviral treatment in selected HCV/HIV co-infected patients.
Methods: 355 samples from 286 HCV/HIV co-infected subjects for whom HCV-RNA (Abbott RealTime) was
requested were analysed also for HCVAg (Abbott ARCHITECT) in order to evaluate the correlation between the two
parameters both in patients treated or untreated for chronic hepatitis C and according to different HCV genotypes.
The differences between percentages were evaluated by chi square or Fisher’s exact test, while mean and median
values were compared by Student’s t test or the Mann–Whitney test, respectively. All differences were considered
significant for a p value <0.05.
Results: HCVAg was detectable on 288/315 sera (91.4%) positive for HCV-RNA and in 5 out of40 (12.5%) sera with
undetectable HCV-RNA for a total concordance of 90.1%. The correlation was fair both in untreated (r = 0.742) and
in treated (r = 0.881) patients and stronger for genotypes 1 and 4 than for genotype 3. Both HCV-RNA and HCVAg
levels were significantly higher (p = 0.028 and p = 0.0098, respectively) in patients infected by genotype 1 than by
genotype 3. The mean ratio of Log values between HCV-RNA (IU/mL) and HCVAg (fmol/liter) was 2.27 ± 1.09 in
untreated and 2.20 ± 0.82 in treated patients (p = n.s.),consistent with a sensitivity of HCVAg corresponding to about
1,000 IU/mL of HCV-RNA, and ranged from 2.21 to 2.32 among HCV genotypes with no significant differences; five
samples (1.4%; 2 genotype 1a or 1c, 3 genotype 3a) showed highly divergent values. The analysis of 18 monitoring
profiles from patients treated with PEG-IFN and Ribavirin showed similar trends, except in one case in which relapse
could be predicted by HCVAg and not by HCV-RNA.
Conclusion: These results suggest that HCVAg represents an adequate tool for determining an ongoing HCV
infection also in HIV co-infected patients, with lower costs and faster turnaround time than HCV-RNA.
Background
The hepatitis C virus (HCV) was first identified in 1989 as
the principal cause of post-transfusion non-A non-B hepa-
titis [1]. Worldwide an estimated 170 million people are
infected with HCV and, due to common routes of trans-
mission 4–5 million are co-infected with the human im-
munodeficiency virus (HIV) [2,3]. The current standard
for diagnosing an active HCV infection is the detection
and quantification of HCV-RNA, also recommended to
monitor the antiviral treatment. Therapy guidelines for
standard treatment with pegylated interferon (PEG-IFN)
plus Ribavirin recommend the discontinuation of the ther-
apy if HCV-RNA decline is <2 log at week 12 or when
HCV RNA is still detectable at week 24 [4]. On therapy
HCV-RNA evaluation is even more crucial to tailor new
therapeutic regimens based on direct acting antivirals
(DAA) drugs [5]. For the measurement of HCV-RNA, a
number of qualitative and quantitative assays are commer-
cially available offering a very low limit of detection and
linear quantification over a broad dynamic range [6-9]. Al-
though the available HCV-RNA testing systems are very
sensitive and have a high-throughput performance, nucleic
acid tests are expensive, labour intensive, and to avoid
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false positive results require technical skills, which limit
their use [10].
A fully automated quantitative immunoassay for measur-
ing the HCV core antigen (ARCHITECT HCVAg, Abbott
Diagnostics, Wiesbaden, Germany) was registered within
EC in 2009 [11]. The assay sensitivity across the different
HCV genotypes ranges from 500 to 3,000 IU/mL of HCV-
RNA [12-14]. Several studies have demonstrated a good
correlation between HCVAg and different HCV-RNA as-
says [12,13,15-17] and suggested that HCVAg could be
used as an alternative to HCV-RNA testing in some set-
tings, for instance in hemodialysis patients [18]. Moreover
HCVAg has been demonstrated to considerably reduce the
window period in 97% of HCV-RNA positive/anti-HCV
antibody negative specimens demonstrating that it repre-
sents a reliable marker of viral replication even in HCV
pre-seroconversion phase [13,19,20]. To date, little data
are available about HCVAg determination in HCV/HIV
co-infected patients: studies carried out so far in this popu-
lation included a small number of samples and did not give
robust information on potential interference of HIV repli-
cative activity on the specificity of HCVAg determination
and on its sensitivity, particularly in the subjects with low
HCV RNA level (HCV-RNA <104 IU/mL) [21].
The aims of the present study were to establish the
clinical sensitivity and to evaluate the concordance and
correlation of HCVAg with HCV-RNA in HCV/HIV co-
infected patients, according to HCV genotypes, and in




Routine samples were selected from HCV/HIV positive
patients admitted to the National Institute for Infectious
Diseases (INMI) “L. Spallanzani” in Roma or to the Re-
gional Hospital “Torrette” in Ancona for whom HCV-
RNA and HIV-RNA testing had been required. The
residual plasma samples were aliquoted, stored at −80°C
and thawed only once for HCVAg testing. All samples
come from the normal routine of our hospitals, therefore
of course we did have access to the basic demographic in-
formation. However, after having collected all these data
the patient list was completely anonymized, so that their
ID recognition was no longer possible. In both Institutions
a very large number of patients are followed for HIV and
HCV infections every year, thus the age and gender infor-
mation will not allow to identify them; in no way it is pos-
sible to link any study result with patient ID. The current
Italian regulation on the protection of personal data have
been strictly observed, in particular: “Codice in materia di
protezione dei dati personali” (d.lg. 30 giugno 2003, n.
196) and “Provvedimento su amministratore di sistema”,
issued by “Garante per la protezione dei dati personali” on
November 27, 2008, and published in Gazzetta Ufficiale,
December 24, 2008.
Samples were selected in order to obtain a balanced dis-
tribution of low, intermediate and high levels of HCV-
RNA and to include sequential specimens from patients
who had started PEG-IFN + RBV treatment for hepatitis
C. Additionally, eleven routine specimens from HIV-
positive individuals with high HIV viral load and negative
for HBsAg, anti-HCV antibodies and HCV-RNA were col-
lected in order to check the specificity of the HCVAg
assay.
Serological and virological assays
HCVAg was quantified by ARCHITECT i2000SR (Abbott
Diagnostics, Wiesbaden, Germany), a fully automated sys-
tem, with a chemiluminescent immunoassay already de-
scribed in detail [11,12]. The linear range of HCVAg
quantification spans between 3.00 and 20,000 femtomoles/
liter (fmol/L) (0.06 and 400 pg/ml), with an automated 1:9
dilution that extends the assay linearity up to 180,000
fmol/L (3,600 pg/mL). Samples with results greater than
the cutoff value (>3 fmol/L) but ≤10 fmol/L were retested
in duplicate and considered “true” positive if confirmed
reactive.
Other serological markers (anti-HCV, HIV Ag/Ab)
were evaluated using the respective assays on the Abbott
ARCHITECT system.
HCV-RNA was quantified by means of a commercial
real-time RT-PCR assay (RealTime™ HCV, Abbott Molecu-
lar Inc, Des Plaines, Il, USA) as specified by the manufac-
turer. The detection limit was 12 IU/mL. HCV genotypes
were determined by VERSANT HCV Genotype 2.0 Assay
(LiPa) (Innogenetics, Ghent, Belgium; distributed by Sie-
mens Healthcare Diagnostics) [22] or by Abbott RealTime
HCV Genotype II Assay (Abbott) [23].
Statistical analysis
The results were collected on a Microsoft Excel worksheet
and analyzed for correlation (Spearman) and agreement
(K statistic) by the Analyse-it software (Analyse Ltd,
Birmingham, UK). The differences between percentages
were evaluated by chi square or Fisher’s exact test, while
mean and median values were compared by Student’s t
test or the Mann–Whitney test, respectively. All differ-
ences were considered significant for a p value ≤0.05.
Results
Three hundred and fifty-five samples obtained from 292
HIV/HCV co-infected patients were included in this
study. Of those, 106 were obtained from 43 patients
under standard treatment with PEG-IFN + Ribavirin for
chronic hepatitis C and 249 were taken from as many
untreated patients.The mean and median ages did not
differ significantly between genders and were 46.2 ± 7.9
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and 47 (range: 20–84) years overall, respectively. As out-
lined in the study protocol, samples were stratified ac-
cording to the HCV-RNA levels (Table 1). Sequential
samples during treatment were available from 41 pa-
tients (3 or more draws from 18 patients, 2 draws from
23 patients).
All the 11 samples from patients negative for HBV and
HCV markers and anti-HIV antibody positive with HIV-
RNA level >105 copies/mL were negative for HCVAg.
The overall concordance between HCVAg and HCV-
RNA was 90.1% and theagreement was fair (kappa =
0.61). On samples from treated patients the qualitative
agreement was significantly lower than on samples from
untreated patients (84.0% vs. 92.8%; p = 0.01 by chi
square). On the whole then, 285 samples were positive
and 35 were negative (i.e. below the detection limit) for
both markers, while 30 were positive for HCV-RNA
(median level: 479 IU/ml; range 13–1,598,723) and nega-
tive for HCVAg and 5, all obtained from treated pa-
tients, were positive for HCVAg (median level: 7.32
fmol/L; range: 6.71-139.96) and negative for HCV-RNA.
Furthermore, 3 out of 12 with RNA levels <1,000 UI/mL
were positive for HCVAg among treated patients vs.
none among untreated.
The positivity rates for HCVAg according to different
levels of HCV-RNA and the median levels are reported in
Table 1. Based on a polynomial regression analysis between
HCV-RNA and HCVAg on the 22 samples positive for
both and with a viral load between 100 and 10,000 IU/mL,
the positivity threshold of the HCVAg assay corresponds
to about 1,000-1,500 IU/mL of HCV-RNA, and indeed
282 out of 292 samples (96.6%) containing >1,000 IU/mL
of HCV-RNA were positive for HCVAg. Five specimens
(1.4%) showed a highly divergent quantitative result be-
tween the two assays, either because HCVAg levels were
higher than HCV-RNA levels or because the Log ratio be-
tween the two parameters exceeded the mean plus 2
standard deviations measured on all samples. Details on
the discrepant specimens, either qualitative or quantitative,
are reported in Table 2.
The correlation between HCV-RNA and HCVAg was
good in treated patients (Spearman r = 0.881; 95% confi-
dence limits (CL) 0.821-0.921) and fair in untreated pa-
tients (Spearman r = 0.742; 95% CL 0.675-0.797; p = 0.05).
Globally, the correlation was r = 0.815 with 95% CL:
0.774-0.849 (Figure 1). The ratio between HCV-RNA and
HCVAg Log levels was also evaluated: the mean ± stand-
ard deviation and median ratio values were 2.20 ± 0.82
and 1.94 in treated patients vs. 2.27 ± 1.09 and 1.99 in un-
treated and (p = n.s.) and 2.25 ± 0.88 and 1.98 overall.
The HCV genotype was available for 245 of the 286
patients (86%), while in 41 cases it was not known due
to low or undetectable HCV-RNA levels. Genotypes 1, 3
and 4 were the most represented as shown in Table 3.
The correlation between HCV-RNA and HCVAg was
fair (Spearman r = 0.816; 95% confidence limits (CL)
0.774-0.851; p < 0.0001) (Figure 1), and was greater for
genotype 1 and 4 (Spearman r = 0.82 and 0.84) than for
genotype 3 (Spearman r = 0.74). The Log ratio between
HCV-RNA and HCVAg was not significantly different
among genotype 1 (2.22 ± 0.80 and 1.94), genotype 3
(2.32 ± 0.88 and 2.00) and genotype 4 (2.21 ± 1.05 and
1.99). The distribution of HCV-RNA and HCVAg levels
according to HCV genotypes 1, 3 and 4 are reported in
Figure 2. Since HCV-RNA levels and HCVAg levels were
not normally distributed, the difference among genotypes
was assessed by a nonparametric test (Mann–Whitney).
The difference was statistically significant for both param-
eters in genotype 1 vs genotype 3 (p = 0.028 for HCV-
RNA and p = 0.0098 for HCVAg), while the difference
between genotype 4 and 3 failed to reach the statistical sig-
nificance (p = 0.122 and 0.114, respectively). No difference
was observed between genotype 1 and genotype 4 (p =
0.902 and 0.578, respectively).
In 17 of the 18 patients sampled 3 or more times dur-
ing PEG-IFN + Ribavirin therapy the behaviour of HCV-
RNA and HCVAg was coincident, as 12 patients showed
a sustained decrease, 2 patients a less pronounced de-
crease and 3 patients no significant variations: two ex-
amples are reported in Figure 3A and B. For one patient




N. HCVAg+ % N. HCVAg+ % N HCVAg+ % Median
<12 23 5 21.7 17 0 0 40 5 12.5 7.32
12-999 12 3 25.0 11 0 0 23 3 13.0 6.04
1000-9999 11 8 100 17 11 64.7 28 19 67.9 16.04
10000-99999 14 14 100 30 30 100 44 44 100 72.71
100000-999999 22 22 100 66 66 100 88 88 100 548.67
≥1000000 24 24 100 108 107 99.1 132 131 99.2 2968.20
Total 106 76 74.5 249 214 85.9 355 290 81.7 770.51
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a significant discrepancy was observed (Figure 3C): both
HCV-RNA and HCVAg declined initially, but while the
former was undetectable on two consecutive draws, taken
2 months apart, HCVAg was still positive at 139.96 and
11.21 fmol/L. On the last draw, both HCV-RNA and
HCVAg were detected (11,050 IU/mL and 40.20 fmol/L,
respectively).
Discussion
HCVAg has been initially proposed as a surrogate marker
of HCV-RNA for blood screening [5] and soon afterwards
it was suggested that the quantitative determination of this
parameter could surrogate RNA testing also in the moni-
toring of chronic HCV infections and possibly also in pa-
tients under therapy [24-27]. The availability of a fully
Table 2 Discrepant results between HCVAg and HCV-RNA
Case Genotype HCVAg HCV-RNA Log ratio Notes
n Fmol/L IU/mLI RNA/Ag
1 3a 6.71 0 na Therapy 12 m, log ratio at T0 1.08, neg for both at 32 m
2 1a 11.21 0 na Therapy 8 m, log ratio at T0 2.46
2 1a 139.96 0 na Therapy 16 m, log ratio at T0 2.46
3 3a 7.32 <12 na Therapy 12 m, log ratio at T0 2.34, log ratio at 8 m 2.92
4 3a 6.82 <12 na Therapy 4 m, log ratio at T0 2.43
5 na 0.00 1142 na Untreated, single specimen
6 3a 0.20 1807 na Untreated, single specimen
7 4 0.54 3468 na Untreated, single specimen
8 3a 1.89 4975 na Untreated, single specimen
9 na 1.78 7939 na Untreated, single specimen
10 3a 1.19 9206 na Untreated, single specimen
11 1a 2.69 1598723 14.44 Untreated, single specimen
12 1c 3,972.47 2097 0.92 Untreated, single specimen
13 1a 7.92 105551 5.59 Untreated, single specimen
14 3a 8.83 40643 4.87 Untreated, single specimen
15 3a 18.96 698555 4.57 Untreated, single specimen
16 3a 31.20 7338172 4.57 Untreated, single specimen
Five samples from four patients positive for HCVAg and negative for HCV-RNA, seven samples negative for HCVAg despite HCV-RNA levels higher than 1,000 UI/mL, five
samples with a Log ratio between the two assays outside the expected range; na, not available; m, months.
Figure 1 Correlation between HCVAg and HCV-RNA on 315 samples from patients with HCV RNA >12 IU/ml. Values are reported on a
logarithmic scale and with different symbols according to genotype. The correlation coefficient (Spearman) was 0.869.
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automated immunoassay with on-board sample pretreat-
ment for the quantitative determination of HCVAg has
brought up a series of new studies. Most of those have
confirmed the original data presented by the manufacturer
[11], reporting a good specificity [12,13,17] and a sensitiv-
ity in the range of 500–3,000 IU/mL of HCV-RNA, ac-
cording to the HCV genotype and possibly to other
factors. Indeed, the theoretical and experimental equiva-
lency between the two parameters was investigated by
Schuettler et al. [28], who established that according to
the HCV structure 1 pg of HCVAg corresponds to
43,000 IU of HCV-RNA, whereas on clinical samples this
ratio was much lower (1 pg = about 7,900 IU of HCV-
RNA). This has been confirmed in subsequent studies
based on different HCV RNA quantification systems
[13-16,18]; in particular, very recently Descamps et al. [14]
found a very significant correlation of HCVAg to HCV-
RNA, measured by TaqMan amplification (r = 0.90; p <
0.001) and an equivalency of 1 pg of HCVAg = 9,755 IU of
HCV-RNA, that equals about 600 IU/mL at the HCVAg
assay threshold of 3 fmol/L. From those data, confirmed
also by our observation, only a portion of the circulating
HCVAg seems to be associated with complete virions, im-
plying that a variable fraction of circulating HCVAg may
be secreted by the infected cells. Additionally the HCVAg
measured by the immunoassay derives also from antigen-
antibody complexes that are disrupted during sample pre-
treatment. Furthermore, it has been observed that also
HCV, like the hepatitis B virus, may be present in the
bloodstream as complete virions and defective particles,
presumably with low or no infectivity [29] especially in the
late phases of infection. The discrepancy between HCV-
RNA and HCVAg production may be large enough in
some instances to justify the huge differences observed in
1.4% of samples in our observation as well as in other
studies [12,13,15] and the combined action of all the above
mentioned factors may help explain why the equivalency
and correlation between viral RNA and core antigen
Table 3 HCV genotypes in the study population of 286 HIV/HCV co-infected patients
Genotype 1 Genotype 2 Genotype 3 Genotype 4 Mixed*
N (%) N (%) N (%) N (%) N(%)
Gender Total N Genotyped N (%) Total NS a b c a/b Total NS a a/c Total NS a Total NS a
Unknown 13
10 6








(76.9) (60.0) (−) (20.0) (20.0) (−)
Female 74
59 33








(79.7) (55.9) (−) (25.7) (11.9) (−)
Male 199
176 78








(88.4) (44.3) (1.7) (33.0) (19.9) (1.1)
Total 286
245 117








(85.7) (47.8) (1.2) (32.2) (18.0) (0.8)
N, number; NS, not subtyped; The two mixed cases (*) were infected by genotype 1a and 3 and genotype 1a and 3a. respectively. Forty-one genotypes (14.3%)
were not available due to very low levels of HCV-RNA.
Figure 2 Distribution of HCV-RNA (A) and HCVAg (B) by HCV
genotype. Significant differences between median values were
observed only between genotypes 1 and 3 for both HCV-RNA
(p = 0.028) and HCVAg (p = 0.0098).
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Figure 3 Monitoring profiles from three patients co-infected by HCV and HIV. The values of HCV-RNA and HCVAg are expressed on a
logarithmic scale as IU/mL and fmol/L. respectively. The trends of the two parameters in the two patients described in Figure 3A and B were
almost identical whereas the patient in Figure 3C showed a persistence of HCVAg positivity and a virological relapse on the following draw.
Dotted line: HCVAg; solid line: HCV-RNA.
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differs among the various studies.Viral variability may also
be implicated in generating these discrepancies, such as
the finding of one specimen with >1 million IU/mL of
HCV-RNA and negative for HCVAg. For instance, it has
been shown that a variability in the core gene products is
able to affect the recognition of circulating HCVAg because
polymorphisms at amino acids 47 to 49 of the core Ag were
responsible for underestimation [30] and that the levels of
HCVAg and ratio of HCV-RNA to HCVAg may be affected
by the polymorphism of the IL28B genotype [31].
In our experience the correlation (r = 0.818) was weaker
than reported by others, as previous studies with the same
HCVAg assay reported r values up to 0.90 or even higher
[14,32]. This does not seem to be ascribed to the relatively
high rate (30%) of samples from treated patients in our se-
lection, since the relationship between these two indexes
of active HCV infections appears stronger in treated than
in untreated patients. Recently, Kuo et al. [32] assayed 405
subjects identified by a community screening for HCVAg
and found a high degree of correlation with HCV-RNA
(R2 = 0.94), concluding that the combined use of anti-
HCV levels and of HCVAg would have a very high pre-
dictive value for viremia, helping to identify individuals
with active HCV infection in the screening of an
asymptomatic population. Indeed, the currently available
HCVAg assay is suitable for the purpose of identifying the
presence of active HCV infection in anti-HCV positive in-
dividuals [16,17,33], bearing also a significant prognostic
value [34].
We analyzed the potential effect of HCV-RNA levels
on the RNA/Ag Log ratio separately in samples from
treated and untreated patients. We did not observe any
significant differences between the two groups, neither
between groups with HCV-RNA levels lower or higher
than 10 IU/mL of HCV-RNA.
The target population of our study was different from
the majority of the other studies on HCVAg, as it was
entirely composed of patients co-infected by HCV and
HIV. The double infection is rather frequent, due to
common routes of transmission [2,35-37], and liver dis-
ease is the second leading cause of death in patients in-
fected by HIV [38].
In Italy HCV infection has a higher prevalence than in
other Western countries [39], and IDUs have repre-
sented the highest risk group for HIV for at least 2 de-
cades, thus the number of co-infected individuals should
be quite high [39,40]. The HCV genotype distribution
gives an indirect confirmation to this hypothesis: while
in Italian population genotypes 1 and 2 appear the most
represented [39], in our study genotype 2 was almost ab-
sent and genotype 4, mainly transmitted by parenteral
routes and linked to drug injection [39,40], is rare in
other settings, while it was observed in 18% of patients
from the present study.
HCV replication appears to be higher in HIV co-
infected than in HCV monoinfected patients as indicated
by previous studies [41,42]. Thus far, only 3 very recent
studies have explored the behaviour of HCV antigen in
HIV/HCV co-infections. Xu et al. [43] have shown a
higher variability of the HCV Core gene sequences and a
more diversified HCV quasispecies population in asso-
ciation with the progressive decrease in the immune
pressure caused by long-term HIV infection, but HIV co-
infection did not seem to influence the correlation be-
tween HCV-RNA and HCVAg. In residents from a rural
village in China Shen et al. [42] have found a high correl-
ation both in 129 HCV-only infected (r = 0.808) and in 98
patients with the double infection (r = 0.952). The results
of Mederacke et al. [21] were substantially similar, with a
96% concordance and a very high correlation (r = 0.97) on
71 samples from 58 co-infected individuals. Our results
were different, since the concordance (91.5%) and correl-
ation (r = 0.816) were both lower. It is also of note that ra-
tio of HCV-RNA/HCVAg log10 levels reported in 16
Chinese co-infected patients [43] were lower and more
homogeneous (1.78 ± 0.16; median 1.74) than in the
present study (2.25 ± 0.88; median 1.98) and not different
from those found in HCV-monoinfected subjects.
Several factors may help explain these discrepancies:
first, our population was numerically much more con-
sistent (355 samples from 292 patients, i.e. almost twice
as many as in the 3 other studies combined). Further-
more no information on the HCV genotype was avail-
able from the latter study while in the former study [21]
most samples were collected from patients infected by
genotype 1 (41/71) or genotype 2 (23/71) and these
Authors found a very high correlation for both, while in
the present study the correlation in genotype 3 infection
was weaker. Finally, a different proportion of patients
undergoing treatment for HCV and host factors related
to the different populations may account for the ob-
served discrepancies observed between this and previous
studies.
The kinetics of HCV-RNA and HCVAg in a subgroup of
18 co-infected patients under treatment for chronic hepa-
titis C was also evaluated and confirms the substantial con-
cordance and similar temporal trends already observed in
other studies [12,25,27], though in some cases the decrease
of HCVAg may be slower as we found samples reactive for
HCVAg and negative or with very low levels of HCV-RNA
only in samples obtained during antiviral treatment for
hepatitis C.We also describe one notable exception, in
which the persistence of HCVAg after the disappearance
of HCV-RNA from the blood stream anticipated a viro-
logical relapse. While the complete mechanisms of inhib-
ition of viral replication and of the production of viral
antigens in patients undergoing treatment for chronic
hepatitis C are still unclear, testing for HCVAg during
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either conventional or DAA-based treatment, as recently
suggested [26,27], will bring only a marginal additional
cost and may enable to identify some cases that will benefit
from a closer monitoring of HCV-RNA levels in order to
anticipate viral rebound.
Conclusions
Testing for HCVAg may represent a suitable option for
assessing the presence and degree of active HCV infec-
tion also in patients co-infected by HIV. As in other
viral infections, the adoption of standardized serological
testing on high-volume automated systems will guaran-
tee a faster turnaround time. This is particularly useful
for the close monitoring requested in the new thera-
peutic options with direct antiviral acting drugs (DAA).
In addition, this approach can help reducing the cost, es-
pecially in terms of personnel, for the initial screening
and routine patient assessment and will allow to focus
the time and skills on more demanding and cumber-
some virological assays.
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